Why the study?
Clozapine-related cardiovascular adverse effects including myocarditis and cardiomyopathy limit its widespread use in treatment-resistant schizophrenia.
Does a slow re-titration and biomarker monitoring protocol allow for safe clozapine rechallenge in a patient with prior clozapine-induced myocarditis?
Does a slow re-titration and biomarker monitoring protocol allow for safe clozapine rechallenge in a patient with prior clozapine-induced myocarditis?
A slow re-titration protocol with careful biomarker monitoring may allow for successful clozapine rechallenge in patients who previously developed clozapine-induced myocarditis.
May support cautious rechallenge after clozapine-induced myocarditis in select cases; leaves open need for prospective protocols.
OBJECTIVE: Protocol for clozapine rechallenge in patients with a history of clozapine-induced myocarditis. METHOD: Clozapine-related cardiovascular adverse effects including myocarditis and cardiomyopathy have limited its widespread use in treatment-resistant schizophrenia. Here, we present a case of clozapine-induced myocarditis and successful cautious rechallenge. Ms. AA, a young female patient with severe psychosis developed myocarditis during her initial clozapine titration phase, which was thus discontinued. Subsequent response to other medications was poor, and she remained significantly disabled. We reviewed blood-based biomarkers identified during the emergence of her index episode of myocarditis and developed a successful clozapine rechallenge protocol, based on careful monitoring of changes in these indices and a very slow clozapine re-titration. RESULTS AND CONCLUSIONS: This protocol may have utility in the management of patients with a history of clozapine-induced myocarditis.
No takes yet. Share an insight, caveat, or question.
Shivakumar et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: